Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the board of directors of Spain’s largest pharma firm Almirall has approved the appointment of Peter Guenter as chief executive effective October 1, 2017.
Mr Guenter joins Almirall from French pharma major Sanofi, where he has worked for the last 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. During his tenure at Sanofi, he held many senior positions including VP Eastern Europe and Northern Europe, VP business management. Before joining Sanofi, he held different positions in sales and marketing at Smith Kline and Ciba Geigy.
“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level,” said Jorge Gallardo, chairman of Almirall.
“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the center of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall,” said Mr Guenter.
Eduardo Sanchiz has been with Almirall for 13 years and was appointed CEO in July 2011. He will transition with Mr Guenter during the month of September.
Source: The Pharma Letter
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).